Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents

CT Bolliger, TG Sutedja, J Strausz… - European Respiratory …, 2006 - Eur Respiratory Soc
Minimally invasive diagnostic and therapeutic approaches in medicine have been applied
for a more selective and tailored approach to reduce patients' morbidity and mortality. The …

[PDF][PDF] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial

…, T Janaskova, J Vansteenkiste, J Strausz… - Journal of Clinical …, 2007 - researchgate.net
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

ERS/ATS statement on interventional pulmonology. European respiratory society/American thoracic society

…, M Marel, M Noppen, J Strausz… - The European …, 2002 - pubmed.ncbi.nlm.nih.gov
… Eur Respir J. 2002 Feb;19(2):356-73. doi: 10.1183/09031936.02.00204602. … 1 , PN
Mathur, JF Beamis, HD Becker, S Cavaliere, H Colt, JP Diaz-Jimenez, JF Dumon, E Edell …

Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European …

…, H Becker, F Stanzel, A Kreuzer, B Schmidt, J Strausz… - Thorax, 2005 - thorax.bmj.com
Background: The potential of autofluorescence bronchoscopy (AFB) to detect precancerous
lesions in the central airways and its role in lung cancer screening is uncertain. A study was …

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial

…, M Krzakowski, A Szczesna, J Strausz… - Journal of clinical …, 2012 - ascopubs.org
Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling …

[HTML][HTML] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX …

…, JF Feng, F Grossi, DW Kim, X Liu, S Lu, J Strausz… - Annals of …, 2016 - Elsevier
Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …

Pathology of chronic obstructive pulmonary disease

M Szilasi, T Dolinay, Z Nemes, J Strausz - Pathology & Oncology …, 2006 - Springer
Chronic obstructive pulmonary disease is one of the leading causes of death and morbidity
worldwide. Despite intensive investigation, its pathology and pathophysiology are not well …

Phenotypes of organ involvement in sarcoidosis

…, Z Kadija, S Pabst, C Grohé, J Strausz… - European …, 2018 - Eur Respiratory Soc
Sarcoidosis is a highly variable, systemic granulomatous disease of hitherto unknown
aetiology. The GenPhenReSa (Genotype–Phenotype Relationship in Sarcoidosis) project …

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell …

…, SJ Green, K Park, S Novello, J Strausz… - Journal of Clinical …, 2010 - ascopubs.org
7500 Background: The Insulin-like growth factor type I receptor (IGF-IR) plays an important
role in normal cellular growth and development and is implicated in the regulation of tumor …

Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis

…, S Pfeifer, DN Männel, J Strausz… - … American review of …, 1992 - epub.uni-regensburg.de
An activation of T-cells that is restricted to the lung has been demonstrated in pulmonary
sarcoidosis. The role of blood monocytes (MO) and alveolar macrophages (AM) in this concept …